MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancer

Summary: Advanced prostate cancers are treated with therapies targeting the androgen receptor (AR) signaling pathway. While many tumors initially respond to AR inhibition, nearly all develop resistance. It is critical to understand how prostate tumor cells respond to AR inhibition in order to exploi...

תיאור מלא

מידע ביבליוגרפי
Main Authors:	Preston D. Crowell, Jenna M. Giafaglione, Anthony E. Jones, Nicholas M. Nunley, Takao Hashimoto, Amelie M.L. Delcourt, Anton Petcherski, Raag Agrawal, Matthew J. Bernard, Johnny A. Diaz, Kylie Y. Heering, Rong Rong Huang, Jin-Yih Low, Nedas Matulionis, Nora M. Navone, Huihui Ye, Amina Zoubeidi, Heather R. Christofk, Matthew B. Rettig, Robert E. Reiter, Michael C. Haffner, Paul C. Boutros, Orian S. Shirihai, Ajit S. Divakaruni, Andrew S. Goldstein
פורמט:	Article
שפה:	English
יצא לאור:	Elsevier 2023-10-01
סדרה:	Cell Reports
נושאים:	CP: Cancer CP: Metabolism
גישה מקוונת:	http://www.sciencedirect.com/science/article/pii/S2211124723012330

אינטרנט

http://www.sciencedirect.com/science/article/pii/S2211124723012330

MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancer

אינטרנט

פריטים דומים